Genentech Notifies 340B Entities of Limited Distribution of Key COVID-19 Drug

Genentech notified 340B entities this week that it is running out of Actemra IV (tocilizumab)—a key tool in treating hospitalized COVID-19 patients.

Biopharmaceutical manufacturer Genentech notified 340B entities this week that it is running out of Actemra IV (tocilizumab)—a key tool in treating hospitalized COVID-19 patients. It told entities they will be subject to the same allocation procedures as other buyers.

The

Read More »

Medicare Trustees Say Part B Drug Payments Will More than Double by 2030

The Medicare Board of Trustees expects Part B reimbursement for physician-administered drugs will more than double to $46.2 billion by 2030.

Medicare Part B reimbursement for physician-administered drugs is projected to rise from $18.7 billion in 2020 to $21.7 billion this year, and then to more than double to $46.2 billion by 2030, the Medicare Board of Trustees reported to Congress

Read More »

In Hurricane Ida’s Wake, HRSA Announces 340B Registration Flexibility in Louisiana and Mississippi

In light of Hurricane Ida, Louisiana and Mississippi health care providers eligible to participate in the 340B program may enroll immediately rather than having to wait until the next quarterly registration period Oct. 1 through 15.

Louisiana and Mississippi health care providers eligible to participate in the 340B program may enroll immediately rather than having to wait until the next quarterly registration period Oct. 1 through 15, the U.S. Health Resources and Services Administration (HRSA) announced

Read More »